Here, we probe the biochemical deficiency at the molecular core of GNAO1 encephalopathy, identify a drug correcting this deficiency, validate it in neuronal cells, and lastly show that the dietary supplementation of the drug rescues defects in a Drosophila model of the disease, identifying the potential therapeutic avenue to treat human patients. This evidence concerns the gene GNAO1 and Encephalopathy.